BioStock: Evaxion to develop novel precision cancer vaccine concept

Evaxion Biotech has announced an expanded commitment to developing precision cancer vaccines by targeting a novel category of tumour antigens called endogenous retroviruses (ERVs). These will be identified with the company’s proprietary target discovery AI-Immunology platform, and proof-of-concept data is expected later this year.

Read the article at biostock.se:

Evaxion to develop novel precision cancer vaccine concept - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/